Objective: To explore the clinical characteristics and prognosis of patients with diffuse large B-cell lymphoma (DLBCL) of the breast.
Methods: The clinical data of 28 DLBCL patients admitted to Shanxi Provincial Cancer Hospital from January 2013 to January 2023 were retrospectively analysed, including 13 cases of primary breast DLBCL (PB-DLBCL) and 15 cases of secondary breast DLBCL (SB-DLBCL), and the data of their clinical manifestations, laboratory tests, pathological examinations, treatment protocols, and follow-up were statistically analyzed.
Results: There were significant differences in IPI score, LDH level and β2- microglobulin between PB-DLBCL and SB-DLBCL patients (P < 0.05). Among the 23 patients with breast DLBCL who received regular treatment, 13 patients achieved complete remission (9 patients with PB-DLBCL and 4 patients with SB-DLBCL) after initial treatment. By the end of follow-up, 11 patients relapsed or progressed (5 patients with PB-DLBCL and 6 patients with SB-DLBCL) and 9 patients died (3 patients with PB-DLBCL and 6 patients with SB-DLBCL). The 5-year OS rate was (75.0±15.3)% in PB-DLBCL group and (32.3±17.1)% in SB-DLBCL group. The 5-year PFS rate was （59.1±19.8）% in PB-DLBCL and 0% in SB-DLBCL group. The 5-year OS rate and PFS rate of PB-DLBCL patients were higher than those of SB-DLBCL patients (P < 0.05); the 5-year OS rate of the combined central preventive treatment group was higher than that of the chemotherapy group (P < 0.05).
Conclusion: Breast DLBCL is divided into two categories: PB-DLBCL and SB-DLBCL. Compared with SB-DLBCL, PB-DLBCL has the characteristics of lower IPI score, LDH, and β2-microglobulin levels. PB-DLBCL patients have a longer survival period. In addition, the prognosis of patients receiving central preventive treatment is more optimistic.
题目: 乳腺弥漫大B细胞淋巴瘤临床特征及预后分析.
目的: 探讨乳腺弥漫大B细胞淋巴瘤（DLBCL）患者的临床特征及预后。.
方法: 回顾性分析2013年1月至2023年1月山西省肿瘤医院收治的28例乳腺DLBCL患者的临床资料，其中原发性乳腺DLBCL（PB-DLBCL）13例、继发性乳腺DLBCL（SB-DLBCL）15例，对其临床表现、实验室检查、病理学检查、治疗方案和随访资料进行统计学分析。.
结果: PB-DLBCL患者与SB-DLBCL患者在IPI评分、LDH、β2- 微球蛋白方面比较，差异有统计学意义（ P < 0.05）。接受规律治疗的23例乳腺DLBCL患者中，13例初始治疗达到完全缓解（PB-DLBCL 9例，SB-DLBCL 4例），至随访截止日期，11例患者复发或进展（PB-DLBCL 5例，SB-DLBCL 6例），9例患者死亡（PB-DLBCL 3例，SB-DLBCL 6例）。PB-DLBCL组、SB-DLBCL组患者5年OS率分别为（75.0±15.3）%和（32.3±17.1）%，PFS率分别为（59.1±19.8）%和0，PB-DLBCL患者5年OS率及PFS率均高于SB-DLBCL患者（ P < 0.05）；联合中枢预防治疗组5年OS率高于单纯化疗组（ P < 0.05）。.
结论: 乳腺DLBCL分为PB-DLBCL和SB-DLBCL两大类，PB-DLBCL与SB-DLBCL相比，具有IPI评分、LDH水平、β2- 微球蛋白较低等特点，且PB-DLBCL患者生存期更长。此外，接受中枢预防治疗患者的预后更为乐观。.
Keywords: breast tumour; diffuse large B-cell lymphoma; clinical features; prognosis.